Global Xerostomia Therapeutics Market - 2022-2029

Global Xerostomia Therapeutics Market - 2022-2029

Market Overview

Xerostomia Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 3.8% during the forecast period (2022-2029).

Xerostomia is defined as dry mouth resulting from reduced or absent saliva flow. Xerostomia is not a disease but is a symptom of toxicity from chemotherapy, head and neck radiotherapy, adverse effects of medications, autoimmune disease, or other conditions such as uncontrolled diabetes, infections, and hormonal changes. Xerostomia occurs commonly in those with Sjögren disease or who are receiving radiation therapy for head and neck cancer. Xerostomia is a common complaint among older adults, affecting approximately 20% of the elderly. Reduced salivary flow can cause difficulties in tasting, chewing, swallowing, and speaking; it can also increase the chance of developing dental decay, demineralizing teeth, tooth sensitivity, and oral infections.

Market Dynamics

The xerostomia therapeutics market growth is driven by several factors, such as an increase in chemotherapy, growing awareness and rising prevalence of xerostomia and associated diseases.

The growing prevalence of xerostomia and associated diseases has increased the demand for xerostomia therapeutics fueling the market growth.

The growing occurrence of xerostomia and related diseases such as hypertension, Parkinson's disorder, Sjogren's syndrome and diabetes positively impact market growth. Diabetes is one of the major causes that causes of dry mouth; there is less moisture for other things when the body is using fluids to make urine, which happens in diabetes. Diabetes hence leads to a dehydrated body and mouth that feels dry. Xerostomia can exacerbate the side effects of diabetes, increasing glucose levels and wreaking havoc on the body. Having xerostomia, especially as a diabetes patient, can lead to rampant tooth decay, which means blood sugar increases as the body tries to fight infection. A dry mouth can also lead to loss of sleep and an altered sense of taste, a condition that presents a metallic or sour taste in the mouth.

Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of xerostomia in the elderly is Sjogren's syndrome. Sjogren's syndrome is the third most common rheumatic autoimmune disorder. The population prevalence of Sjogren's syndrome is 0.2%, with an incidence of 4 cases per 100,000 per year. Sjogren's is 20 times more common in females than males. Sjogren's syndrome attacks the glands that make tears and saliva; this causes a dry mouth and dry eyes, increasing the cases of xerostomia.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global xerostomia therapeutics market growth.

The High cost, ineffectiveness and common and uncommon side effects of available treatments for xerostomia are restraining the growth of the global xerostomia therapeutics market. In addition, stringent U.S. Food and Drug Administration (FDA) regulations for drug approval can hamper market growth. For instance, Amifostine-sold under the trade name Ethyol is the only drug available validated by the U.S FDA for protecting radiation-induced xerostomia.

Industry analysis.

The global xerostomia therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

In the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of the Xerostomia therapeutics. Furthermore, the socializing restriction made it difficult to get regular healthcare checkups, leaving most Xerostomia patients undetected, negatively impacting the global Xerostomia therapeutics market.

Segment Analysis/B>

Salivary stimulants are presumed to be prevailing throughout the forecast period (2022-2029)

Salivary stimulants are expected to be the largest market shareholder over the period forecast (2022-2029). Topical salivary stimulant flow products include over-the-counter sugar-free gums, mints, and candies. Salivary stimulants include the sialagogues pilocarpine hydrochloride (Salagen®) and cevimeline hydrochloride (Evoxac®). Pilocarpine and cevimeline bind to muscarinic receptors, stimulating exocrine gland activity (such as salivary and sweat glands) and increasing smooth muscle tone in the gastrointestinal and urinary tracts. Common adverse effects include sweating, headache, GI discomfort, nausea, increased lacrimation, urinary frequency, and palpitations. Sialogogic drugs are substances designed to stimulate salivary secretion as they affect the systemic pathway. Using sugar-free chewing gum or tablet can increase salivary secretion and improve the sensation of dry mouth with gustatory and masticatory stimulation. These products include fluoride, chlorhexidine, calcium phosphate, and xylitol releasers. Salivary stimulants are highly popular as they are readily available and can be taken without adverse effects.

Geographical Analysis

The North American region is overshadowing the global xerostomia therapeutics market.

North America was dominating the xerostomia therapeutics market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in cancer and xerostomia-associated disorders such as Sjogren’s disorder, a highly aware population, advanced healthcare infrastructure, favorable government initiatives and growth in research and development. As per the National Cancer Institute, in 2020, around 1,806,590 new cancer cases were diagnosed in the US, and 606,520 people died. These numbers increase yearly, along with the causes such as lifestyle changes, smoking, etc. The US is very advanced in healthcare, and the population is generally aware; this leads to growing chemotherapy treatment cases leading to xerostomia.

Similarly, other diseases associated with xerostomia, such as Parkinson’s and Sjogren’s syndrome, are also on the rise in the region; Sjogren’s occurs in 0.1 to 1 percent of the population and is one of the most prevalent autoimmune diseases. Nine out of 10 patients are women. Initiatives launched by various organizations, such as the “5-year breakthrough goal” by Sjogren’s Syndrome Foundation, focus on faster diagnosis and better treatment.

Competitive Landscape

Some of the major key players in the market are GlaxoSmithKline, Church & Dwight Co., Inc., Colgate-Palmolive Company, Acacia Pharma Group plc, Hikma Pharmaceuticals plc, Lupin Ltd., Parnell Pharmaceuticals Inc., Pendopharm, Virginia Head and Neck Therapeutics, Inc., Pfizer Inc. and Sun Pharmaceutical Industries Ltd. In the xerostomia therapeutics market, GlaxoSmithKline will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, contributing to the growth of the global xerostomia therapeutics market. For instance, on February 11, 2021, Virginia Head and Neck Therapeutics, Inc. introduced the Voutia device, which provides continuous relief from xerostomia.

Daiichi Sankyo Company

Overview

Daiichi Sankyo Company, Limited is a leading global pharmaceutical company and is the second-largest pharmaceutical company in Japan. As of March 2020, it has 15,348 employees. Daiichi Sankyo Company was founded in 2005 and is headquartered in Tokyo, Japan.

Product Portfolio

Daiichi Sankyo Company’s xerostomia product portfolio has Evoxac.

The global xerostomia therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.